Shares of [finviz_code ticker=ACOR item=2 value=”Acorda Therapeutics, Inc.”] (NASDAQ:[finviz_code ticker=ACOR item=1 value=”ACOR”]) are currently up by more than [finviz_code ticker=ACOR item=60 value=”-2.20%”] from the open today and are trading at $[finviz_code ticker=ACOR item=65 value=”24.40″]. More than [finviz_code ticker=ACOR item=67 value=”909,617″] shares have exchanged hands compared to an average trading volume of [finviz_code ticker=ACOR item=63 value=”690.27K”]. At the current pps, the market cap stands at $[finviz_code ticker=ACOR item=6 value=”1.12B”]. The stock prices of [finviz_code ticker=ACOR item=2 value=”Acorda Therapeutics, Inc.”] (NASDAQ:[finviz_code ticker=ACOR item=1 value=”ACOR”]) are currently trading at [finviz_code ticker=ACOR item=57 value=”-34.69%”] below its 52 week high and [finviz_code ticker=ACOR item=58 value=”48.78%”] above its 52 week low.
[finviz_code ticker=ACOR item=2 value=”Acorda Therapeutics, Inc.”] (NASDAQ:[finviz_code ticker=ACOR item=1 value=”ACOR”]) has been in the news for all the right reasons. Recently, [finviz_code ticker=ACOR item=2 value=”Acorda Therapeutics, Inc.”] (NASDAQ:[finviz_code ticker=ACOR item=1 value=”ACOR”]) announced that Phase 3 clinical data of CVT-301, showing a statistically significant improvement in motor function in people with Parkinson’s disease experiencing OFF periods. CVT-301 is an investigational, inhalable formulation of levodopa (L-dopa). It is being studied as a treatment for OFF periods in people with Parkinson’s disease taking an oral carbidopa / levodopa regimen. OFF periods refer to the re-emergence of Parkinson’s symptoms.
“We are greatly encouraged by the efficacy and safety results of this trial, which validate the positive Phase 2b results,” said Burkhard Blank, M.D., Chief Medical Officer of Acorda. “We would like to express our gratitude to the study volunteers and clinical investigators who participated in this trial to advance our understanding of this potentially important therapy for people with Parkinson’s.”
The SPAN-PD trial had three arms: CVT-301 84 mg and 60 mg doses (equivalent to 50 mg and 35 mg fine particle doses, respectively), and placebo. The primary endpoint of the study was the change at Week 12 in Unified Parkinson’s Disease Rating Scale-Part 3 (UPDRS III) score relative to placebo at 30 minutes post-treatment for the 84 mg dose. UPDRS III change for the 84 mg dose was -9.83 compared to -5.91 for placebo (p=0.009). UPDRS III is a validated scale, which measures Parkinson’s motor impairment.
The safety profile of CVT-301 in this study was consistent with that observed in the Phase 2b trial. Spirometry and diffusing capacity of the lung for carbon monoxide (DLCO) tests showed no notable pulmonary safety signals. The Company is currently conducting two studies to assess the long-term safety profile of CVT-301. Up to 12-month data from these studies are expected by the end of the first quarter of 2017.
The Company plans to file a New Drug Application (NDA) in the United States by the end of the second quarter of 2017, pending results of the long-term safety studies. The Company also plans to file a Marketing Authorization Application (MAA) in Europe by the end of 2017, pending additional data analyses.
Peter LeWitt, M.D., M.Med.Sc., Director of the PD and Movement Disorders Program at Henry Ford Hospital and lead investigator of the study said, “The re-emergence of Parkinson’s disease symptoms has a major negative impact on the lives of people with this disease, as well as on their families and care partners. Managing symptoms of OFF periods continues to be a significant unmet need for people taking oral carbidopa/levodopa regimens. Delivering levodopa by the pulmonary route offers an important treatment option for people with Parkinson’s disease.”
Detailed trial results will be presented at a future medical meeting. Read The Full Release
[finviz_code ticker=ACOR item=2 value=”Acorda Therapeutics, Inc.”] (NASDAQ:[finviz_code ticker=ACOR item=1 value=”ACOR”]) is all set to announce its earnings on [finviz_code ticker=ACOR item=68 value=”Feb 14/b”]. As per Zack’s analyst ratings, [finviz_code ticker=ACOR item=2 value=”Acorda Therapeutics, Inc.”] (NASDAQ:[finviz_code ticker=ACOR item=1 value=”ACOR”]) currently has an average brokerage rating of [quandl_code ticker=ACOR item=ZAR|RATING_MEAN value=”1.86″]. On a scale of 1 to 5, a rating of 1 or 2 would indicate a buy, and a rating of 4 or 5 would signify a sell recommendation. A rating of 3 would indicate a hold on the stock. The consensus target price on (NASDAQ:[finviz_code ticker=ACOR item=1 value=”ACOR”]) is $[quandl_code ticker=ACOR item=ZAR|TP_MEAN_EST value=”36.166″] with a high of $[quandl_code ticker=ACOR item=ZAR|TP_HIGH_EST value=”60″] and a low of $[quandl_code ticker=ACOR item=ZAR|TP_LOW_EST value=”21″].
Let’s take a look at the technical analysis.
[intr_chart ticker=ACOR src=”http://www.financialstrend.com/wp-content/uploads/2017/02/25536-ACOR4.png”]
[intr_bto ticker=ACOR content=”ICAgIFRoZSBCYXJjaGFydCBUZWNobmljYWwgT3BpbmlvbiByYXRpbmcgaXMgYSAxMDAlIEJ1eSB3aXRoIGEgU3Ryb25nZXN0IHNob3J0IHRlcm0gb3V0bG9vayBvbiBtYWludGFpbmluZyB0aGUgY3VycmVudCBkaXJlY3Rpb24uICAgICBMb25nZXIgdGVybSwgdGhlIHRyZW5kIHN0cmVuZ3RoIGlzIE1heGltdW0uICAgTG9uZyB0ZXJtIGluZGljYXRvcnMgZnVsbHkgc3VwcG9ydCBhIGNvbnRpbnVhdGlvbiBvZiB0aGUgdHJlbmQuICAgICBUaGUgbWFya2V0IGlzIGFwcHJvYWNoaW5nIG92ZXJib3VnaHQgdGVycml0b3J5LiBCZSB3YXRjaGZ1bCBvZiBhIHRyZW5kIHJldmVyc2FsLiAgICA=”]
The The Exponential Moving Average (EMA) is similar to a simple moving average (average price over a set period) but it utilizes a weighting factor that exponentially declines from the most recent data point (recent prices are weighted higher than oid prices). EMA analysis compares the short term (5 days and 13 days), intermediate term (20 days) and long term (50 days) EMA’s. The respective EMA’s will give bullish signals when trading above trailing EMA’s and below the current price and vice versa. EMA alerts include crossovers (i.e the 5 day EMA crosses above/below the 20 day EMA) and EMA convergencies (5 day EMA equivalent to 13 day EMA). [ema_code ticker=ACOR].
The relative strength index (RSI) is a momentum osciallator that is able to measure the velocity and magnitude of stock price changes. Momentum is calculated as the ratio of positive price changes to negative price changes. The RSI analysis compares the current RSI against neutral(50), oversold (30) and overbought (70) conditions. Alerts will inform you when stocks recede from oversold/overbought levels or breakthrough neutral (50). [rsi_code ticker=ACOR]
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.